Why the study?
Does cangrelor inhibit the binding of clopidogrel and prasugrel active metabolites to P2Y12 receptors in vitro?
Population
In vitro model assessing functional P2Y12 receptor number using a (33)P-2MeSADP binding assay
Comparison
Cangrelor co-incubated with clopidogrel active… vs Cangrelor alone, clopidogrel AM alone, or…
Design
Preclinical
Authors
Loading...
May warrant caution with immediate clopidogrel/prasugrel transition after cangrelor; leaves open clinical relevance of this in vitro interaction.
Does cangrelor inhibit the binding of clopidogrel and prasugrel active metabolites to P2Y12 receptors in vitro?
Cangrelor competitively inhibits the binding of clopidogrel and prasugrel active metabolites to the P2Y12 receptor in vitro, providing a mechanistic basis for avoiding overlapping administration during PCI.
Judge et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: